A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT)

被引:30
|
作者
Saremi, Aramesh [1 ]
Bahn, Gideon D. [2 ]
Reaven, Peter D. [1 ]
机构
[1] Phoenix VA Hlth Care Syst, Phoenix, AZ USA
[2] Cooperat Studies Program Coordinating Ctr, Hines, IL USA
基金
美国国家卫生研究院;
关键词
ABDOMINAL AORTIC CALCIFICATION; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; CORONARY-ARTERY; GLUCOSE CONTROL; MORTALITY; COMPLICATIONS; SYMPTOMS; ASSOCIATION; APOPTOSIS;
D O I
10.2337/dc15-2107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVETo determine whether a link exists between serious hypoglycemia and progression of atherosclerosis in a substudy of the Veterans Affairs Diabetes Trial (VADT) and to examine whether glycemic control during the VADT modified the association between serious hypoglycemia and coronary artery calcium (CAC) progression.RESEARCH DESIGN AND METHODSSerious hypoglycemia was defined as severe episodes with loss of consciousness or requiring assistance or documented glucose <50 mg/dL. Progression of CAC was determined in 197 participants with baseline and follow-up computed tomography scans.RESULTSDuring an average follow-up of 4.5 years between scans, 97 participants reported severe hypoglycemia (n = 23) or glucose <50 mg/dL (n = 74). Serious hypoglycemia occurred more frequently in the intensive therapy group than in the standard treatment group (74% vs. 21%, P < 0.01). Serious hypoglycemia was not associated with progression of CAC in the entire cohort, but the interaction between serious hypoglycemia and treatment was significant (P < 0.01). Participants with serious hypoglycemia in the standard therapy group, but not in the intensive therapy group, had approximate to 50% greater progression of CAC than those without serious hypoglycemia (median 11.15 vs. 5.4 mm(3), P = 0.02). Adjustment for all baseline differences, including CAC, or time-varying risk factors during the trial, did not change the results. Examining the effect of serious hypoglycemia by on-trial HbA(1c) levels (cutoff 7.5%) yielded similar results. In addition, a dose-response relationship was found between serious hypoglycemia and CAC progression in the standard therapy group only.CONCLUSIONSDespite a higher frequency of serious hypoglycemia in the intensive therapy group, serious hypoglycemia was associated with progression of CAC in only the standard therapy group.
引用
收藏
页码:448 / 454
页数:7
相关论文
共 50 条
  • [41] Observation on Renal Outcomes in the Veterans Affairs Diabetes Trial
    Agrawal, Lily
    Azad, Nasrin
    Emanuele, Nicholas V.
    Bahn, Gideon D.
    Kaufman, Derrick G.
    Moritz, Thomas E.
    Duckworth, William C.
    Abraira, Carlos
    [J]. DIABETES CARE, 2011, 34 (09) : 2090 - 2094
  • [42] Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort
    Hunt, Kelly J.
    Jenkins, Alicia J.
    Fu, Dongxu
    Stevens, Danielle
    Ma, Jian-xing
    Klein, Richard L.
    Azar, Madona
    Zhang, Sarah X.
    Lopes-Virella, Maria F.
    Lyons, Timothy J.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (10)
  • [43] Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort
    Hunt, Kelly J.
    Jaffa, Miran A.
    Garrett, Sara M.
    Luttrell, Deirdre K.
    Lipson, Kenneth E.
    Lopes-Virella, Maria F.
    Luttrell, Louis M.
    Jaffa, Ayad A.
    [J]. DIABETES CARE, 2018, 41 (04) : 840 - 846
  • [44] The Genetic Link Between Diabetes and Atherosclerosis
    Ross, Stephanie
    Gerstein, Hertzel
    Pare, Guillaume
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (05) : 565 - 574
  • [45] Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
    Zhou, Jin J.
    Schwenke, Dawn C.
    Bahn, Gideon
    Reaven, Peter
    [J]. DIABETES CARE, 2018, 41 (10) : 2187 - 2194
  • [46] Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial
    Lipska, Kasia J.
    Laiteerapong, Neda
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23): : 2266 - 2267
  • [47] Rosiglitazone treatment and cardiovascular disease in the veterans affairs diabetes trial
    Florez, H. J.
    Moritz, T.
    Marks, J.
    Reda, D.
    Warren, S.
    Duckworth, W.
    Abraira, C.
    [J]. DIABETOLOGIA, 2008, 51 : S370 - S370
  • [48] Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
    Florez, H.
    Reaven, P. D.
    Bahn, G.
    Moritz, T.
    Warren, S.
    Marks, J.
    Reda, D.
    Duckworth, W.
    Abraira, C.
    Hayward, R.
    Emanuele, N.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (10): : 949 - 955
  • [49] Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial
    Alele, Jimmy D.
    Luttrell, Louis M.
    Hollis, Bruce W.
    Luttrell, Deirdre K.
    Hunt, Kelly J.
    [J]. ATHEROSCLEROSIS, 2013, 228 (02) : 502 - 507
  • [50] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes
    Abraira, C
    Colwell, J
    Nuttall, F
    Sawin, CT
    Henderson, W
    Comstock, JP
    Emanuele, NV
    Levin, SR
    Pacold, I
    Lee, HS
    Silbert, CK
    Cxypoliski, R
    Vasquez, M
    Kernan, D
    Niewoehner, C
    Backes, M
    Bradley, M
    Bradley, M
    Crow, R
    Rubino, F
    Bushnell, D
    Pfeifer, M
    Service, FJ
    Howard, B
    Chew, E
    Hoogwerf, B
    Seigel, D
    Clark, CM
    Olefsky, JM
    Porte, D
    Sussman, KE
    Johnson, N
    Christine, B
    Tir, K
    Sather, M
    Day, P
    Morgan, N
    Deykin, D
    Gold, J
    Huang, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 181 - 188